Background: To evaluate the possibility of preventing endotoxin induced renal damage by p38-MAPK inhibition in a human model. Design and Methods: Twenty-one healthy young male volunteers received 4 ng/kg Escherichia coli endotoxin as a single dose. Four groups of volunteers received an oral dose of placebo or 350, 700 or 1400 mg RWJ-67657, a p38-MAPK inhibitor, 20 min before endotoxin infusion. Urine samples were collected at set time intervals. The urinary excretion rate of β 2 -microglobulin and N-acetyl-β-D-glucosaminidase, as indicators of tubular dysfunction was determined. Results: There was a significant increase of β 2 -microglobulin and N-acetyl-β-D-glucosaminidase urine excretion rate after endotoxin infusion in the placebo group. p38-MAPK inhibition prevented the increase of markers for tubulopathy. Conclusions: Endotoxin infusion induces measurable tubular damage. Blocking the p38-MAPK may prevent this damage. The mechanism is unclear, but blocking TNF-α release is a possible explanation.
INTRODUCTION
Sepsis is a major cause of multiple organ failure and death in the intensive care unit. Attempts to improve survival by interfering with the immune system have failed for various reasons. Several inflammatory mediators are implicated in sepsis. We recently described that inhibition of the intracellular p38 mitogen activated protein kinase (p38-MAPK), a new target, may have a substantial effect on inflammation. p38-MAPK is a key enzyme in intracellular signaling and is involved in regulation of cytokine response, membrane receptor expression and cell survival by phosphorylation of other signaling proteins and transcription factors. RWJ-67575 is a highly specific inhibitor of p38-α-MAPK, the isoform of p38-MAPK, most relevant to inflammation. 1 Our data for healthy human volunteers support the concept that p38-MAPK inhibition exerts effects that are due to inhibition of cytokine synthesis and neutrophil activation. Based on these data, p38-MAPK inhibition might be suggested as a novel intervention in patients with sepsis and multiple organ failure. [2] [3] [4] [5] [6] Administration of i.v. endotoxin is a unique and safe procedure for the evaluation of the pathophysiology of inflammation and sepsis in healthy human volunteers.
In this study, we investigated whether renal impairment, a major component of multiple organ failure, can be diminished by p38-MAPK inhibition. We, therefore, used β 2microglobulin and N-acetyl-β-D-glucosaminidase (NAG) urinary excretion as early markers for tubular damage in this human endotoxemia model. β 2 -Microglobulin is a small peptide present on the membrane of several cell types. It plays a role in the intracellular transport of immunoglobulins and in antigen presentation by HLA-1. Its production is at a stable level in healthy persons and it is filtered by the glomerulus. Resorption in the proximal tubule is 99.9%, and an increase in the urinary excretion of β 2 -microglobulin is, therefore, an indicator of tubular dysfunction. NAG is a lysosomal enzyme that is not filtered by the glomerulus. Urinary NAG is, therefore, of tubular origin and can serve as a measure of tubulopathy. [7] [8] [9] 
PATIENTS AND METHODS

Drug, study design and subjects
RWJ-67657, 4-[4-(4-fluorophenyl)-1-(3-phenylpropyl)-5-(4-pyrindinyl)-1H-imidazol-2-yl]-3-butyn-1-ol, was supplied in an oral pharmaceutical formulation by R.W. Johnson Pharmaceutical Research Institute, Bassersdorf, Switzerland.
After local ethics committee approval and completion of written informed consent forms, 21 healthy male subjects, mean age 29 years (range, 19-44 years), were admitted to the research wing of our intensive care unit the evening before medication and endotoxin infusion. Selection of healthy volunteers was based on medical history and on physical, hematological and biochemical examination.
A catheter was inserted in the radial artery for blood sampling and continuous monitoring of heart rate and blood pressure. At 30 min before endotoxin infusion, a single oral dose of RWJ-67657 was administered. Three dose levels were placebo-controlled tested: placebo (n = 6), 1400 mg (n = 4), 700 mg (n = 6) and 350 mg (n = 5). At time point zero, endotoxin (Escherichia coli, batch EC-6, US Pharmacopeia, Twinbrook Parkway, Rockville, MD, USA) was administered at a dose of 4 ng/kg body weight (10,000 endotoxin units/mg) as a 1-min infusion. Blood for biochemical analysis was drawn pre-dose and until 24 h after endotoxin infusion via an in-dwelling catheter. Samples were immediately placed on ice, centrifuged (1500g, 15 min, 4°C) and stored at -80°C until assayed. Urine was collected over the intervals -12 h to immediately pre-dose, immediately pre-dose to 2 h post-dose, 2-4, 4-8, 8-12, and 12-24 post-dose. The urine was frozen immediately at -20°C for later laboratory determinations.
The β 2 -microglobulin assay (Abbott AXSYM system) is based on the micro-particle enzyme immune assay (MEIA) technology for quantitative measurements in urine. A colorimetric assay (Boehringer Mannheim Biochemical) was used for the determination of NAG in urine. Both assays were performed according to the manufacturers' instructions. Creatinine clearance was calculated for a 12-h sample period before endotoxin and 12 h after endotoxin infusion from U creat x U volume /time x P creat .
Statistical analysis
Data are presented as mean (± SEM) or median (range) and expressed as excretion rate (concentration x flow). The urine collection interval -12 h until immediately pre-dose period was considered baseline. The 4-24 h post-endotoxin infusion is defined as post-dose. The excretion rate of β 2microglobulin and NAG from 4-24 h post-dose was compared with baseline and between groups and analyzed using the Mann Whitney U-test. A two-tailed P value < 0.05 was considered statistically significant. 
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RESULTS
Clinical symptoms
Healthy male subjects treated with placebo drug during endotoxin infusion showed a flu-like syndrome with chills, increased heart rate (HR) and decreased mean arterial pressure (MAP), muscle pain, and headache. The HR/MAP ratio showed a significant dose-dependent effect (1400 mg RWJ-67657 -r = 0.72, P = 0.0002; 700 mg RWJ-67657 -r = 0.50; P = 0.02; and 350 mg RWJ-67657 -r = 0.67; P = 0.001) as described in detail previously. 2, 4 No unexpected events occurred.
The post-dose excretion rate was compared with baseline values for the placebo group and the three dose levels of RWJ-67657 tested (Fig. 1A) . No statistically significant changes from baseline were observed in the RWJ-67657-dosed volunteers. Since there was no dose response effect detected, the data for the three different RWJ-67657 dosages were pooled post-dose (Fig. 1B) . The post-dose urinary β 2 -microglobulin excretion was significantly different between placebo and pooled RWJ-67657 dosages (P = 0.0044)
N-acetyl-β-D-glucosaminidase
The post-dose urinary excretion rate was compared with baseline values for the placebo group and the three dose levels of RWJ-67657 tested. No statistically significant change from baseline was observed in the RWJ-67657dosed volunteers ( Fig. 2A) . A slight increase in excretion rate was found at 0-2 h after endotoxin infusion and RWJ-67657 administration. The differences from placebo were, however, not statistically significant. Because of a lack of clear dose-response effects of RWJ-67657, data from the different RWJ-67657 dosages were pooled postdose and compared with placebo (Fig. 2B) . The post-dose urinary excretion rate was significantly different between placebo and RWJ-67657 ( Fig. 2B; P = 0 
DISCUSSION
Our results show that in the human endotoxin model with only mild clinical symptoms tubulopathy can be detected and can be influenced by inhibition of p38-MAPK with RWJ-67657. We chose tubular enzymes to evaluate renal dysfunction because they are more sensitive for detecting early renal dysfunction than serum and urine creatinine determinations. 8,9 β 2 -Microglobulin is produced by leukocytes. During sepsis or endotoxemia, there may be an increased release of β 2 -microglobulin. A normal tubule has, however, a large reserve capacity and an increased load of β 2 -microglobulin will not directly lead to an increased urinary excretion. Urinary NAG excretion is specific for renal pathology. Therefore, our measurement of both proteins showing the same pattern in excretion rate in this model makes any alternative explanation other than tubulopathy unlikely.
We pooled the data of various dose steps since no clear dose relationship in excretion rate of either proteins was found. In our model, organ damage is mild and can be inhibited by the lowest dose step. Probably, it would require a more severe, unethical toxic effect of endotoxin to show a clear RWJ-67657 dose-response curve.
404 Zijlstra, Tulleken, Ligtenberg et al. The mechanism for tubular dysfunction is still not clear and, consequently, the mechanism by which prevention works is also not understood. [10] [11] [12] In a mouse model of endotoxemia, TNF-α is a major player in inducing renal failure. 13, 14 In our model, this might also be the case because the time of increase of tubular dysfunction is 2 h after the maximum peak of TNF-α production. The abrogation of the TNF-α response by p38-MAPK inhibition would than lead to prevention of impairment of renal function.
The cellular components of inflammation are also involved in endotoxin-induced renal failure. 10, 11 The upregulation of adhesion molecules on the endothelium and leukocytes as well as cell activation is inhibited by RWJ-67657 and probably contribute to renal protection in our model. 2, 5 In sepsis, clotting is activated leading to the formation of microthrombi that may cause ischemic damage in organs such as the kidney. In our study, the volunteers did not show thrombocytopenia or abnormal coagulation parameters. Although there were trace amounts of fibrin degeneration products found in the circulation of some volunteers, it was not compatible with diffuse intravascular coagulopathy. 2, 4 Systemic hypotension with renal hypoperfusion plays a role in severe sepsis and septic shock. In our study, no hypotension was found among the volunteers. 4 Endotoxininduced production of vasoactive compounds (e.g. nitric oxide) can change local blood flow distribution and lead to relative hypoperfusion of the renal medulla with ischemic damage as a consequence. RWJ-67657 is not a vasoactive drug but by, for example, inhibition of up-regulation of inducible nitric oxide synthetase (iNOS), it may have secondary effects on local blood flow control. p38-MAPK is involved in apoptosis in some cell types. Apoptotic mechanisms are also involved in acute renal failure in endotoxemia and sepsis. 12 Whether p38-MAPK inhibition is responsible for renal protection by affecting apoptosis remains speculative.
CONCLUSIONS
Tubular dysfunction as measured by urinary β 2 -microglobulin and NAG excretion rate is induced by endotoxin and can be prevented by inhibition of p38-MAPK. The fact that not only clinical symptoms and parameters of inflammation can be influenced by p38-MAPK inhibition but also parameters for end-organ damage should stimulate the study of signal transduction inhibitors as a therapeutic modality in inflammatory diseases such as sepsis.
